Literature DB >> 28392208

Minimal effects of prolonged smoking abstinence or resumption on cognitive performance challenge the "self-medication" hypothesis in schizophrenia.

Douglas L Boggs1, Toral S Surti1, Irina Esterlis2, Brian Pittman3, Kelly Cosgrove2, R Andrew Sewell2, Mohini Ranganathan2, Deepak Cyril D'Souza4.   

Abstract

One prominent, long-standing view is that individuals with schizophrenia smoke cigarettes more than the general population to "self-medicate" cognitive deficits and other symptoms. This study tested the self-medication hypothesis by examining the effects of smoking abstinence and resumption on cognition in patients with schizophrenia. Nicotine-dependent smokers with schizophrenia (n=26) were trained on a cognitive battery and then hospitalized to achieve and maintain confirmed abstinence from smoking for ~1 week. Cognition was tested while smoking as usual (baseline), one day after smoking cessation (early abstinence), ~1 week later (extended abstinence), and within ~3 weeks of resuming smoking (resumption). The test battery included measures of processing speed, attention, conflict resolution, verbal memory, working memory, verbal fluency, and executive function to evaluate multiple cognitive domains affected by schizophrenia. Positive and negative symptoms of schizophrenia, depressive symptoms, and dyskinesia were also measured at baseline and after prolonged abstinence. There were no significant changes in global cognitive test performance with smoking cessation, abstinence, or resumption. There were small decreases in a measure of processing speed and delayed verbal recall with abstinence, but these findings failed to survive adjustments for multiple comparisons. Surprisingly, in this within subject "On-Off-Off-On" design, there were no significant effects of early or prolonged abstinence from smoking on cognitive and behavioral measures in smokers with schizophrenia. The results of this study challenge the widely held "self-medication" hypothesis of smoking and schizophrenia, question the extent of pro-cognitive effects of smoking and nicotine in schizophrenia, and support encouraging smoking cessation in schizophrenia. Published by Elsevier B.V.

Entities:  

Keywords:  Abstinence; Cognition; Nicotine; Schizophrenia; Smoking; Tobacco; Withdrawal

Mesh:

Substances:

Year:  2017        PMID: 28392208      PMCID: PMC5630481          DOI: 10.1016/j.schres.2017.03.047

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  58 in total

Review 1.  Impaired cognitive inhibition in schizophrenia: a meta-analysis of the Stroop interference effect.

Authors:  René Westerhausen; Kristiina Kompus; Kenneth Hugdahl
Journal:  Schizophr Res       Date:  2011-09-19       Impact factor: 4.939

Review 2.  Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies.

Authors:  Terry E Goldberg; Richard S E Keefe; Robert S Goldman; Delbert G Robinson; Philip D Harvey
Journal:  Neuropsychopharmacology       Date:  2010-01-20       Impact factor: 7.853

3.  Comorbidity of severe psychotic disorders with measures of substance use.

Authors:  Sarah M Hartz; Carlos N Pato; Helena Medeiros; Patricia Cavazos-Rehg; Janet L Sobell; James A Knowles; Laura J Bierut; Michele T Pato
Journal:  JAMA Psychiatry       Date:  2014-03       Impact factor: 21.596

Review 4.  A review of neurobiological vulnerability factors and treatment implications for comorbid tobacco dependence in schizophrenia.

Authors:  Victoria C Wing; Caroline E Wass; Debra W Soh; Tony P George
Journal:  Ann N Y Acad Sci       Date:  2011-11-30       Impact factor: 5.691

5.  Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms.

Authors:  Kristi A Sacco; Angelo Termine; Aisha Seyal; Melissa M Dudas; Jennifer C Vessicchio; Suchitra Krishnan-Sarin; Peter I Jatlow; Bruce E Wexler; Tony P George
Journal:  Arch Gen Psychiatry       Date:  2005-06

6.  Nicotine effects in adolescence and adulthood on cognition and α₄β₂-nicotinic receptors in the neonatal ventral hippocampal lesion rat model of schizophrenia.

Authors:  Sarah A Berg; Alena M Sentir; Richard L Bell; Eric A Engleman; R Andrew Chambers
Journal:  Psychopharmacology (Berl)       Date:  2014-11-13       Impact factor: 4.530

7.  Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction.

Authors:  Deepak Cyril D'Souza; Walid Michel Abi-Saab; Steven Madonick; Kimberlee Forselius-Bielen; Anne Doersch; Gabriel Braley; Ralitza Gueorguieva; Thomas B Cooper; John Harrison Krystal
Journal:  Biol Psychiatry       Date:  2005-03-15       Impact factor: 13.382

8.  The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls.

Authors:  Ruth S Barr; Melissa A Culhane; Lindsay E Jubelt; Rana S Mufti; Michael A Dyer; Anthony P Weiss; Thilo Deckersbach; John F Kelly; Oliver Freudenreich; Donald C Goff; A Eden Evins
Journal:  Neuropsychopharmacology       Date:  2007-04-18       Impact factor: 7.853

Review 9.  Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings.

Authors:  G W Dalack; D J Healy; J H Meador-Woodruff
Journal:  Am J Psychiatry       Date:  1998-11       Impact factor: 18.112

10.  Varenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized Trial.

Authors:  Robert C Smith; Revital Amiaz; Tian-Mei Si; Lawrence Maayan; Hua Jin; Sylvia Boules; Henry Sershen; Chunbo Li; Juanjuan Ren; Yanhong Liu; Mary Youseff; Abel Lajtha; Alessandro Guidotti; Mark Weiser; John M Davis
Journal:  PLoS One       Date:  2016-01-05       Impact factor: 3.240

View more
  7 in total

1.  Nicotine Self-administration Is Not Increased in the Methylazoxymethanol Acetate Rodent Model of Schizophrenia.

Authors:  Jillian J Weeks; Laura E Rupprecht; Anthony A Grace; Eric C Donny; Alan F Sved
Journal:  Nicotine Tob Res       Date:  2020-02-06       Impact factor: 4.244

2.  Demographics, clinical characteristics and cognitive symptoms of heavy smokers and non-heavy smokers in Chinese male patients with chronic schizophrenia.

Authors:  Shuochi Wei; Dongmei Wang; Huixia Zhou; Luyao Xia; Yang Tian; Qilong Dai; Rongrong Zhu; Wenjia Wang; Dachun Chen; Meihong Xiu; Li Wang; Xiangyang Zhang
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-04-26       Impact factor: 5.760

Review 3.  Impact of Nicotine on Cognition in Patients With Schizophrenia: A Narrative Review.

Authors:  Violeta Spasova; Saqib Mehmood; Amjad Minhas; Rabia Azhar; Silpa Anand; Sondous Abdelaal; Sunder Sham; Tabssum M Chauhan; David Dragas
Journal:  Cureus       Date:  2022-04-20

4.  CDP-choline and galantamine, a personalized α7 nicotinic acetylcholine receptor targeted treatment for the modulation of speech MMN indexed deviance detection in healthy volunteers: a pilot study.

Authors:  Joelle Choueiry; Crystal M Blais; Dhrasti Shah; Dylan Smith; Derek Fisher; Vadim Illivitsky; Verner Knott
Journal:  Psychopharmacology (Berl)       Date:  2020-08-27       Impact factor: 4.530

5.  Additive Effect of Cigarette Smoking on Gray Matter Abnormalities in Schizophrenia.

Authors:  Naoto Yokoyama; Hitoshi Sasaki; Yasuo Mori; Miki Ono; Kousuke Tsurumi; Ryosaku Kawada; Yukiko Matsumoto; Yujiro Yoshihara; Genichi Sugihara; Jun Miyata; Toshiya Murai; Hidehiko Takahashi
Journal:  Schizophr Bull       Date:  2018-04-06       Impact factor: 9.306

6.  The pillars of health: influence of multiple lifestyle behaviors on body mass index and depressive symptoms in adult twins.

Authors:  Glen E Duncan; Ally R Avery; Siny Tsang; Nathaniel F Watson; Bethany D Williams; Eric Turkheimer
Journal:  BMC Public Health       Date:  2022-08-05       Impact factor: 4.135

7.  Smoking as a Common Modulator of Sensory Gating and Reward Learning in Individuals with Psychotic Disorders.

Authors:  Alexis E Whitton; Kathryn E Lewandowski; Mei-Hua Hall
Journal:  Brain Sci       Date:  2021-11-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.